2型糖尿病的个体化肠促胰岛素治疗 - Suppr

Suppr

超能文献

Individualised incretin-based treatment for type 2 diabetes.

作者信息

Nauck Michael A, Meier Juris J

机构信息

Diabeteszentrum Bad Lauterberg, D-37431 Bad Lauterberg im Harz, Germany.

出版信息

Lancet. 2010 Aug 7;376(9739):393-4. doi: 10.1016/S0140-6736(10)60998-1. Epub 2010 Jun 26.

DOI:10.1016/S0140-6736(10)60998-1

PMID:20580425

Abstract

摘要

相似文献

Individualised incretin-based treatment for type 2 diabetes.

Lancet. 2010 Aug 7;376(9739):393-4. doi: 10.1016/S0140-6736(10)60998-1. Epub 2010 Jun 26.

Sitagliptin and metformin--novel combination therapy.

Expert Opin Pharmacother. 2011 Mar;12(4):641-6. doi: 10.1517/14656566.2011.556113. Epub 2011 Feb 4.

[Programs for continuing medical education: a session; 7. Recent trends in treatment of diabetes mellitus].

Nihon Naika Gakkai Zasshi. 2014 Mar 10;103(3):657-64. doi: 10.2169/naika.103.657.

Summaries for patients: Does adding exenatide to insulin treatment benefit patients with type 2 diabetes?

Ann Intern Med. 2011 Jan 18;154(2):I-40. doi: 10.7326/0003-4819-154-2-201101180-00301. Epub 2010 Dec 6.

Type 2 diabetes: the end of clinical inertia.

South Med J. 2007 Aug;100(8):765-6. doi: 10.1097/SMJ.0b013e3180f60827.

[GLP-1: a new therapeutic principle for the treatment of type 2 diabetes mellitus].

Med Klin (Munich). 2010 Mar;105(3):163-75. doi: 10.1007/s00063-010-1026-6.

Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus.

Diabetes Obes Metab. 2012 Oct;14(10):882-92. doi: 10.1111/j.1463-1326.2012.01595.x. Epub 2012 Apr 17.

Sitagliptin or exenatide once weekly for type 2 diabetes: comparison of the clinical trials.

Expert Opin Pharmacother. 2011 Sep;12(13):2055-67. doi: 10.1517/14656566.2011.576671. Epub 2011 May 3.

[Insulin secretion is increased depending on glucose.. Metabolism regulation in type 2 diabetes mellitus over five paths].

MMW Fortschr Med. 2009 May 7;151(19):50.

Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.

Diabetes Obes Metab. 2012 Aug;14(8):762-7. doi: 10.1111/j.1463-1326.2012.01603.x. Epub 2012 Apr 24.

引用本文的文献

Comparative efficacy and tolerability of currently approved incretin mimetics: A systematic analysis of placebo-controlled clinical trials.

Diabetes Obes Metab. 2025 Jul;27(7):3736-3746. doi: 10.1111/dom.16398. Epub 2025 Apr 11.

A comprehensive review on the glucoregulatory properties of food-derived bioactive peptides.

Food Chem X. 2022 Feb 2;13:100222. doi: 10.1016/j.fochx.2022.100222. eCollection 2022 Mar 30.

Design of glucagon-like Peptide-1 receptor agonist for diabetes mellitus from traditional chinese medicine.

Evid Based Complement Alternat Med. 2014;2014:385120. doi: 10.1155/2014/385120. Epub 2014 May 6.

Clinical application of glucagon-like Peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus.

Endocrinol Metab (Seoul). 2013 Dec;28(4):262-74. doi: 10.3803/EnM.2013.28.4.262.

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.

Nat Rev Endocrinol. 2012 Dec;8(12):728-42. doi: 10.1038/nrendo.2012.140. Epub 2012 Sep 4.

SUMO downregulates GLP-1-stimulated cAMP generation and insulin secretion.

Am J Physiol Endocrinol Metab. 2012 Mar 15;302(6):E714-23. doi: 10.1152/ajpendo.00486.2011. Epub 2012 Jan 10.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验